CEO, Brady Grainer, From BioCorRx®Inc. Paves Pathway Towards Possible FDA Approval on “Stock Day” Podcast; Aims to Fight Opioid Crisis

PHOENIX, Jan. 22, 2018 (GLOBE NEWSWIRE) -- The Uptick Newswire “Stock Day” podcast keeps investors up to date on the latest penny stock news by bringing transparency in the micro-cap side of the market. Connect with “Stock Day” and to over 600+ CEO interviews on the OTC, Pink Sheets and micro-cap news from around the world by following Stock Day’s YouTube, Google Play and iTunes. After many recent news announcements from the company Everett Jolly, CEO and host of “Stock Day”, was honored to have CEO Brady Grainer from BioCorRx® Inc. (OTCQB:BICX) (“Company”) back onto the show.

Noting that the stock price of the Company has doubled since the last appearance Mr. Jolly allows Mr. Grainer the opportunity to discuss the latest developments of the long-sought FDA approval. Mr. Grainer introduces the two operational portions of the Company; the substance abuse treatment portion as well as a pharmaceutical research and development program which aims at taking the first naltrexone implant through the U.S. Food and Drug Administration regulatory approval process.

In a December 2017 appearance on Fox & Friends, a Fox News Channel morning program, Mr. Grainer discussed the success of a recent BioCorRx®BICX102 implant recipient. BioCorRx® has developed a Naltrexone implant that is used along with Cognitive Behavioral Therapy (CBT) and peer support groups in treatment of opioid and alcohol abuse. Naltrexone is a medication that blocks the euphoric effects of alcohol as well as opioids thus reducing the cravings for these substances. Currently this recovery program is offered at several treatment centers throughout the United States but cost remains a complication for the Company.

BICX102 is the naltrexone implant in which the Company is seeking FDA approval and the National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) have both shown interest in the project. BioCorRx® submitted their development plan to the FDA in December and is scheduled to meet with the U.S. Food and Drug Administration (FDA) scheduled on January 24, 2018. Mr. Granier believes that an FDA approval will increase the likelihood that insurance companies will begin to cover the implant.

“Naltrexone has been approved itself four times by the FDA so there is not a lot of question about how naltrexone works or how safe naltrexone is, really we are looking at more on the delivery of it” Mr. Grainer explains. “There are more things that [the FDA] want to see on the safety and procedure of it.” President Donald Trump declared the opioid crisis as a national health emergency back in August of 2017. This sets a high demand of treatment options for those afflicted by this crisis.

The BioCorRx® Recovery Program is currently sold to alcohol and substance abuse treatment centers, providing some current revenues for the Company. Mr. Grainer plans to continue fighting to get the FDA approval for the implant as well as would like to inform the public about the track record of success that the implant, used in conjunction with The BioCorRx® Recovery Program, has had. For the latest treatment resources Mr. Grainer encourages those who may be suffering from substance abuse, or who know someone who may benefit from treatment options, to visit the treatment side of the company at www.BeatAddiction.Com.

To Hear the Interview in its entirety, Click Here:

About Uptick Newswire and the “Stock Day Podcast”
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona with its new host Kathryn Donnelly.

Follow us and keep an eye on Uptick’s YouTubeTwitter, and Facebook for additional radio and video shows produced by Uptick!

Investors Hangout is a proud sponsor of Stock Day and Uptick Newswire encourages listeners to visit BioCorRx’s message board on:

About BioCorRx

BioCorRx Inc. (OTCQB:BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx® Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.

Investor Relations:
Crescendo Communications, LLC
212-671-1020 x304

Uptick Newswire LLC
Everett Jolly, CEO/Founder
10000 N. 31st Avenue C307
Phoenix, AZ 85051

Source: Uptick Newswire

Source: BioCorRx Inc.